Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Engineering small extracellular vesicles: Unlocking the brain's secret passage for central nervous system therapies

Zhou J., Pu Y., Ren X., Li L., Chen Z., Lo EH.

Narrative Review on Face & Skin, published in J Cereb Blood Flow Metab (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Cereb Blood Flow Metab (2026)
Reported sample size
—
Source database
Europe PMC
PMID
40536171
PMCID
PMC12179118
DOI
10.1177/0271678x251348816
Citations
1

Abstract (original English)

Small extracellular vesicles (sEVs), naturally occurring extracellular vesicles, play a pivotal role in intercellular communication and have gained significant attention for their potential in treating central nervous system (CNS) diseases. Due to their ability to cross the blood-brain barrier (BBB) and deliver therapeutic cargo, sEVs are considered a promising vehicle for targeted drug delivery in CNS disorders. Recent advancements in sEVs engineering-such as surface modifications, genetic alterations, and cargo optimization-have substantially enhanced their specificity and therapeutic efficacy. This review examines the relevance of endogenous sEVs in CNS and highlights recent developments in sEVs engineering and cargo optimization. We then discuss strategies for targeting specific brain cells, including neurons, microglia, and endothelial cells. Although clinical applications show promising potential, they remain in early stages, with challenges including large-scale production, precise tracking, standardized preparation, and efficient long-distance targeting. Further research into the cellular mechanisms of sEVs -mediated delivery and the functional differences between sEVs derived from various cell types is crucial for advancing their clinical translation in CNS therapies.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Blood-Brain BarrierBrainAnimalsHumansCentral Nervous System DiseasesDrug Delivery SystemsExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research